Trulieve Cannabis (NYSE:TRLV) Trading Down 5% - Time to Sell?

Key Points

• Trulieve Cannabis shares fell about 5% to $11.07 in Friday trading, with volume down 84% from the average session. The stock remains above its 50-day moving average of $9.99.
• Analyst sentiment is mixed, with ratings spanning Buy, Hold and Sell. MarketBeat reports an average rating of “Hold” and a consensus price target of $15, implying potential upside from the current price.
• The company exceeded quarterly expectations, reporting $0.11 in EPS versus a $0.06 consensus estimate and $271 million in revenue versus $268.82 million expected. However, insiders sold 1.42 million shares worth approximately $12.1 million over the past 90 days.

Trulieve Cannabis Corp. (NYSE:TRLV - Get Free Report)'s stock price traded down 5% on Friday . The stock traded as low as $11.42 and last traded at $11.07. Approximately 121,247 shares traded hands during trading, a decline of 84% from the average session volume of 764,057 shares. The stock had previously closed at $11.65.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TRLV. Wall Street Zen downgraded shares of Trulieve Cannabis from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Trulieve Cannabis in a research note on Friday, September 11th. Cantor Fitzgerald reiterated an "overweight" rating and set a $15.00 price objective on shares of Trulieve Cannabis in a research report on Friday, August 7th. Finally, Zacks Research raised shares of Trulieve Cannabis to a "hold" rating in a research note on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Trulieve Cannabis has an average rating of "Hold" and a consensus target price of $15.00.

Trulieve Cannabis Stock Down 6.1%

The company's fifty day moving average price is $9.99.

Trulieve Cannabis (NYSE:TRLV - Get Free Report) last posted its earnings results on Friday, August 7th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. The business had revenue of $271.00 million during the quarter, compared to the consensus estimate of $268.82 million. Equities research analysts expect that Trulieve Cannabis Corp. will post 0.31 EPS for the current year.

Insider Buying and Selling at Trulieve Cannabis

In other news, CEO Kim Rivers sold 136,811 shares of the company's stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $8.76, for a total transaction of $1,198,464.36. Following the completion of the sale, the chief executive officer owned 1,476,913 shares in the company, valued at approximately $12,937,757.88. This represents a 8.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,421,626 shares of company stock valued at $12,051,085 over the last ninety days. 3.79% of the stock is owned by insiders.

About Trulieve Cannabis

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes, manufactures and sells medical and adult-use cannabis products. Its product portfolio includes flower, pre-rolls, concentrates, edibles, tinctures, capsules and topical products, marketed under the Trulieve brand and other affiliated brands.

The company sells its products through a network of company-operated dispensaries and, where permitted, through wholesale and other distribution channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.